إيفاسيترابيب

Chemical data

Formula

C31H36F6N6O2

Molecular weight

638.6 g/mol

IUPAC name

4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexane-1-carboxylic acid

SMILES

CC1=CC(=C2C(=C1)[C@H](CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C

InChIKey

IHIUGIVXARLYHP-UXNJHFGPSA-N

XLogP

7.7

Polar surface area

87.4 Ų

H-bond donors

1

H-bond acceptors

13

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Phase 3

Molecule type

Small molecule

Indications

cardiovascular disease, Disorder of lipid metabolism, Hypercholesterolemia, hyperlipidemia

via ChEMBL · EBI

• Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.The New England journal of medicine · 2017
• Evacetrapib.Current cardiology reports · 2012
• Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.Cardiology in review · 2017
• Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials.Prostaglandins, leukotrienes, and essential fatty acids · 2021
• CETP inhibitor evacetrapib enters mouse brain tissue.Frontiers in pharmacology · 2023

via PubMed

Wikidata facts

Subclass of

carboxylic acid

Mass

638.280394

via Wikidata · CC0